REPROCELL has launched StemEdit, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. The platform integrates high-fidelity genome engineering with predictive off-target modelling, designed to support research, translational development and future clinical applications. [Read more…]
REPROCELL Introduces StemEdit Platform
What is the difference between totipotent, pluripotent, and multipotent?
When learning about stem cells, a common question is, what is the difference between totipotent, pluripotent, and multipotent cells? The answer is simple.
The key differences between these cells are:
- When each appears during the process of human development.
- Their degree of “flexibility” to become other cell types. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2026
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
The Future of Stem Cell Therapy as Treatment for Autism
Treatment for autism is an increasingly important pursuit, as the Center for Disease Control and Prevention (CDC) estimates:
- 1 in 59 children has been identified with autism spectrum disorder (ASD) [Read article]
- Autism occurs in all racial, ethnic, and socioeconomic groups. [Read article]
- Studies in Asia, Europe, and North America have identified ASD to have a prevalence rate of between 1% and 2%. [Data table]
With autism spectrum disorder (ASD) affecting between 1-2% of the population, the condition is becoming of increasing importance and a treatment for autism is becoming a highly sought-after medical breakthrough.
Leading Competitors within the Induced Pluripotent Stem Cell (iPSC) Market
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 200
- Next Page »